Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 12Thoracic 3Plasma cell 3Other hematologic neoplasm 3Lymphoid 3Head & Neck 3Gastrointestinal 3Myeloid 2Gynecologic 2Endocrine 2Dermatologic 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Sarcoma 2Neoplasm Metastasis 2Gastrointestinal Stromal Tumors 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Osteosarcoma 1Nonseminomatous germ cell tumor 1Neoplasms 1Multiple Myeloma 1Leukemia, Hairy Cell 1Glioma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Temozolomide 51Bevacizumab 23Radiotherapy 16Magnetic Resonance Spectroscopy 16Irinotecan 15Carmustine 12Erlotinib Hydrochloride 10Carboplatin 8Surgical Procedures, Operative 6O(6)-benzylguanine 6Imatinib Mesylate 6Filgrastim 6Cyclophosphamide 6Biopsy 6sargramostim 5aldesleukin 5X-Rays 5Thalidomide 5Phantoms, Imaging 5Chemotherapy, Adjuvant 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5temsirolimus 4Topotecan 4Specimen Handling 4Sirolimus 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Etoposide 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × trametinib × Sarcoma × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡